Khiron Life Sciences Celebrates Big Growth in Colombia and Expands into New Latin American and European Markets
According to New Frontier Data
Why Ocugen Shares Are Getting Hammered Today
Ocugen Inc (NASDAQ: OCGN) shares were trading 22.18% lower off the open Thursday at $7.24 after the company announced it will pursue a biologics license application path for its COVID-19 vaccine instead of emergency use authorization.
Amgen’s Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients’ Lives, Mid-Stage Study Shows
Amgen Inc (NASDAQ:AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients…
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ:AKBA) for the development and commercialization of…
FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron’s COVID-19 Antibody Cocktail
The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 monoclonal antibody cocktail for those with COVID-19 who…
Surface Oncology’s SRF388 Shows Promising Anticancer Activity in Pretreated Patients
Surface Oncology (NASDAQ:SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be…
4D pharma To Stop Testing Asthma Med in COVID-19 Patients
4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma.